Celldex shares slip after skin drug trial results
Celldex Therapeutics said its experimental drug significantly reduced disease activity in two late-stage trials in patients with a chronic skin condition, but shares fell nearly 15% as safety concerns weighed on the result.
By Siddhi MahatoleCelldex Therapeutics said on Tuesday its experimental drug significantly reduced disease activity in two late-stage trials of patients with a chronic skin condition, clearing a key hurdle toward a U.S. regulatory filing.Shares of the New Jersey-based company fell nearly 15% as inv…